Cargando…

In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin

The present study was focused on formulating and evaluating clarithromycin (CLR) containing niosomal formulation for in vitro and in vivo pharmacokinetic behavior. Niosomal formulations (empty and drug loaded) were prepared by using different ratio of surfactant (various Span grades 20, 40, 60, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Shilakari Asthana, Gyati, Sharma, Parveen Kumar, Asthana, Abhay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884864/
https://www.ncbi.nlm.nih.gov/pubmed/27293976
http://dx.doi.org/10.1155/2016/6492953
_version_ 1782434428164767744
author Shilakari Asthana, Gyati
Sharma, Parveen Kumar
Asthana, Abhay
author_facet Shilakari Asthana, Gyati
Sharma, Parveen Kumar
Asthana, Abhay
author_sort Shilakari Asthana, Gyati
collection PubMed
description The present study was focused on formulating and evaluating clarithromycin (CLR) containing niosomal formulation for in vitro and in vivo pharmacokinetic behavior. Niosomal formulations (empty and drug loaded) were prepared by using different ratio of surfactant (various Span grades 20, 40, 60, and 80) and cholesterol by thin film hydration method and were evaluated for in vitro characteristics, stability studies, and in vivo study. Dicetyl phosphate (DCP) was added to the niosomal formulation. Various pharmacokinetic parameters were determined from plasma of male SD rats. Span 60 containing niosomal formulation NC(2) (cholesterol to surfactant ratio 1 : 1) displayed highest entrapment efficiency with desired particle size of 4.67 μm. TEM analyses showed that niosomal formulation was spherical in shape. Niosomes containing Span 60 displayed higher percentage of drug release after 24 h as compared to other formulations. NC(2) formulation was found to be stable at the end of the study on storage condition. Various pharmacokinetic parameters, namely, AUC, AUMC, and MRT of niosomal formulation, were found to be 1.5-fold, 4-fold, and 3-fold plain drug, respectively. The present study suggested that niosomal formulations provide sustained and prolonged delivery of drug with enhance bioavailability.
format Online
Article
Text
id pubmed-4884864
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48848642016-06-12 In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin Shilakari Asthana, Gyati Sharma, Parveen Kumar Asthana, Abhay Scientifica (Cairo) Research Article The present study was focused on formulating and evaluating clarithromycin (CLR) containing niosomal formulation for in vitro and in vivo pharmacokinetic behavior. Niosomal formulations (empty and drug loaded) were prepared by using different ratio of surfactant (various Span grades 20, 40, 60, and 80) and cholesterol by thin film hydration method and were evaluated for in vitro characteristics, stability studies, and in vivo study. Dicetyl phosphate (DCP) was added to the niosomal formulation. Various pharmacokinetic parameters were determined from plasma of male SD rats. Span 60 containing niosomal formulation NC(2) (cholesterol to surfactant ratio 1 : 1) displayed highest entrapment efficiency with desired particle size of 4.67 μm. TEM analyses showed that niosomal formulation was spherical in shape. Niosomes containing Span 60 displayed higher percentage of drug release after 24 h as compared to other formulations. NC(2) formulation was found to be stable at the end of the study on storage condition. Various pharmacokinetic parameters, namely, AUC, AUMC, and MRT of niosomal formulation, were found to be 1.5-fold, 4-fold, and 3-fold plain drug, respectively. The present study suggested that niosomal formulations provide sustained and prolonged delivery of drug with enhance bioavailability. Hindawi Publishing Corporation 2016 2016-05-16 /pmc/articles/PMC4884864/ /pubmed/27293976 http://dx.doi.org/10.1155/2016/6492953 Text en Copyright © 2016 Gyati Shilakari Asthana et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shilakari Asthana, Gyati
Sharma, Parveen Kumar
Asthana, Abhay
In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin
title In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin
title_full In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin
title_fullStr In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin
title_full_unstemmed In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin
title_short In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin
title_sort in vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884864/
https://www.ncbi.nlm.nih.gov/pubmed/27293976
http://dx.doi.org/10.1155/2016/6492953
work_keys_str_mv AT shilakariasthanagyati invitroandinvivoevaluationofniosomalformulationforcontrolleddeliveryofclarithromycin
AT sharmaparveenkumar invitroandinvivoevaluationofniosomalformulationforcontrolleddeliveryofclarithromycin
AT asthanaabhay invitroandinvivoevaluationofniosomalformulationforcontrolleddeliveryofclarithromycin